drugset / Trial / NCT06980597
A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
NaSingle-groupOpen-labelTreatment
Summary
This study aims to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of OL-108 in relapsed/refractory autoimmune diseases.
Timeline
- Start
- 2025-06
- Primary completion
- 2027-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OL-108 | Cell therapy | — | Intravenous |